主要目标：临床试验每组的无进展生存期(PFS) 次要目标：临床试验每组的至肿瘤进展时间(TTP)；临床试验每组的客观缓解率 (ORR)；临床试验每组的疾病控制率 (DCR)；临床试验每组的总生存期(OS)；根据不良事件的发生率和严重程度评估YIV-906联合索拉非尼组合的安全性和耐受性；临床试验每组中的生活质量 (QoL) 变化；确定YIV-906对于索拉非尼药代动力学（PK）的影响。探索性目标：为了研究YIV-906联合索拉非尼在患者中的生物学效应，为肝癌的早期检测和精确治疗以及预后分析奠定基础，本研究将对一系列生物标志物进行分析，其中包括：AFP、AST、ALT、细胞因子、趋化因子、HBV血清学标志物、HBV病毒载量、循环肿瘤DNA以及血清代谢组学；分析上述可溶性生物标志物结果与临床治疗终点的相关性；分析可溶性生物标志物之间的相关性；比较两组患者体内的肠道和口腔有益和致病菌群组成，包括治疗前和治疗后的对比。

开始日期2021-04-15

申办/合作机构

Yiviva, Inc.初创企业

[+2]

NCT04000737 / Unknown status临床2期

A Phase II Randomized Placebo-Controlled Study Investigating The Combination Of YIV-906 And Sorafenib (Nexavar®) In HBV (+) Patients With Advanced Hepatocellular Carcinoma

The aim of this study is to compare the efficacy and safety of YIV-906 plus standard-of-care sorafenib versus those of sorafenib alone as a first-line systemic treatment for patients with Hepatitis B (+) associated advanced hepatocellular carcinoma.
YIV-906 (PHY906, KD018) is an immune system modulator. Clinical and preclinical research suggests that YIV-906 could act to enhance the body's immune response to fight cancer and increase the anti-tumor activity of sorafenib and protect and repair the gastrointestinal tract by reducing inflammation and promoting tissue regeneration.
Inspired by a 1,800-year-old traditional medicine still in use today, YIV-906 is a botanical drug candidate, composed of an extract of four herbs and administered in oral capsule form.
The CALM (Combination of YIV-906 and Sorafenib to treat Advanced Liver cancer in a Multi-center study) trial is a multi-regional, randomized, placebo-controlled study.

开始日期2020-01-10

申办/合作机构

Yiviva, Inc.初创企业

NCT02178644 / Completed临床1期IIT

Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer

This pilot study focuses on KD018 and will investigate the effect of this agent on reducing the Gastrointestinal (GI) toxicity associated with combined modality therapy of locally-advanced rectal cancer.

开始日期2014-07-01

申办/合作机构

Yale University

100 项与 YIV-906 相关的临床结果

登录后查看更多信息

100 项与 YIV-906 相关的转化医学

登录后查看更多信息

100 项与 YIV-906 相关的专利（医药）

登录后查看更多信息

项与 YIV-906 相关的文献（医药）

2024-06-01·Journal of Gastrointestinal Oncology

A single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer

Article

作者: Liu, Shwu-Huey ; Higgins, Susan A ; Lam, Wing ; Hochster, Howard ; Zaheer, Wajih ; Cheng, Yung-Chi ; Johung, Kimberly L ; Kortmansky, Jeremy ; Lacy, Jill ; Verma, Nipun ; Stein, Stacey ; Cecchini, Michael ; Reddy, Vikram

Background:

Pre-operative chemoradiation for rectal cancer is often associated with severe gastrointestinal (GI) toxicity which can interrupt, delay, and/or lead to termination of treatment. In this study, we evaluated whether the addition of YIV-906, a novel herbal medicine proven to reduce GI toxicity associated with chemotherapy could also reduce GI side effects during standard pre-operative capecitabine and pelvic radiation therapy (RT) in the neoadjuvant setting for the treatment of locally advanced rectal cancer.

Methods:

This single arm clinical study enrolled 24 patients between Dec 23, 2014-Sep 17, 2018 at Smilow Cancer Hospital, a comprehensive cancer center at Yale New Haven Hospital. All patients were age ≥18 years, Eastern Cooperative Oncology Group 0-1 and with histologically confirmed T3-T4 and N0-N2, M0 adenocarcinoma of the rectum. Median follow-up was 61.9 months. All patients received concurrent pelvic external beam RT (50.4 Gy in 28 fractions), YIV-906 (taken orally 800 mg twice daily on days 1-4 of RT each week), and oral capecitabine delivered in a neo-adjuvant fashion, followed by definitive surgery. Toxicity was assessed weekly during radiation and until acute symptoms resolved and then at 28 days, 4 months, 7 months and 10 months. Toxicities were graded in accordance with Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

Results:

At the time of surgery, 4 patients (16.7%) had a complete or near-complete response. At a median follow-up of 61.9 months, the mean overall survival (OS) of our patient cohort was 74.9 months [95% confidence interval (CI): 67.3-82.5]. The estimated 5-year OS was 82.0%. We observed 0% acute grade 4 toxicities, and only two cases of acute grade 3 diarrhea (8.3%).

Conclusions:

The addition of YIV-906 to capecitabine based chemoradiation for locally advanced rectal cancer led to reduced rates of GI toxicity compared to historical controls, in particular grade 3 or greater diarrhea. These findings suggest YIV-906 should be evaluated in a randomized clinical trial to further assess potential reductions in the toxicity profile of chemoradiation for GI cancers.

2024-01-01·Integrative cancer therapies

Efficiency of Protective Interventions on Irinotecan-Induced Diarrhea: A Systematic Review and Meta-Analysis

Review

作者: He, Bing ; Zhang, Wei ; He, Yanxi ; Qi, Xiaoyi ; Xiong, Xia ; Liang, Sicheng ; Wang, Xuan ; Wang, Yu ; Zhao, Wenjing ; Wu, Lili ; Deng, Mingming

Background::

Irinotecan is widely used in the treatment of various solid tumors, but the adverse effects from it, especially diarrhea, limit its use. Several clinical trials of prophylactic treatment of irinotecan-induced diarrhea (IID) have been ongoing, and some of the data are controversial. This encouraged us to conduct a meta-analysis of the effects of interventions on preventing IID.

Method::

This systematic review was conducted based on the PRISMA statement. We performed literature searches from PubMed, Web of Science, Embase, and Cochrane Library. The number registered in PROSPERO is CRD42022368633. After searching 1034 articles in the database and references, 8 studies were included in this meta-analysis.

Result::

The RR of high-grade diarrhea and all-grade diarrhea were 0.31 ( I2 = 51%, 95% CI: 0.14-0.69; P = .004) and .76 ( I2 = 65%, 95% CI: 0.62-0.93; P < .008) respectively, thus the use of intervention measures for preventing IID is effective, and the risk reduction of high-grade diarrhea was more significant. Subgroup analysis revealed that the monotherapy group (RR: 0.48, 95% CI: 0.21-1.13, I2 = 0%) and combination therapy group (RR: 0.14, 95% CI: 0.06-0.32, I2 = 0%) in the risk of high-grade diarrhea had no significant heterogeneity within the groups, and traditional herbal medicines (Kampo medicine Hangeshashin-to, PHY906 and hot ironing with Moxa Salt Packet on Tianshu and Shangjuxu) were effective preventive measures (RR:0.20, 95% CI: 0.07-0.60, I2 = 0%). The Jadad scores for traditional herbal medicines studies were 3, and the follow-up duration was only 2 to 6 weeks.

Conclusion::

This systematic review and meta-analysis suggest that preventive treatments significantly reduced the risk of high-grade and all-grade diarrhea, confirming the efficacy in the incidence and severity of IID, among which traditional herbal medicines (baicalin-containing) provided a protective effect in reducing the severity of IID. However, the traditional herbal medicines studies were of low quality. Combined irinotecan therapy can obtain better preventive effects than monotherapy of IID. These would be helpful for the prevention of IID in clinical practice.

2022-01-01·Frontiers in fungal biology

A Secondary Metabolite Secreted by Penicillium citrinum Is Able to Enhance Parastagonospora nodorum Sensitivity to Tebuconazole and Azoxystrobin.

Article

作者: Chudakova, Kseniya ; Shcherbakova, Larisa ; Voinova, Tatiana ; Arslanova, Lenara ; Kartashov, Maksim ; Dzhavakhiya, Vitaly

Parastagonospora nodorum causes glume and leaf blotch of wheat, a harmful disease resulting in serious losses in grain yield. In many countries including Russia, fungicidal formulations based on triazoles and on triazoles combined with strobilurins are used to control this fungus. However, their prolonged application may promote the selection of fungicide-resistant strains of P. nodorum leading to significant attenuation or even loss of fungicidal effect. Chemosensitization of plant pathogenic fungi with natural compounds represents a promising strategy for mitigating fungicide resistance and other negative impacts of fungicides. In this work, we applied a chemosensitization approach towards P. nodorum strains non-resistant or resistant to tebuconazole or azoxystrobin using 6-demethylmevinolin (6-DMM), a metabolite of Penicillium citrinum. The resistant strains were obtained by the mutagenesis and subsequent culturing on agar media incorporated with increasing doses of Folicur^® EC 250 (i.e., tebuconazole) or Quadris^® SC 250 (i.e., azoxystrobin). Test strains m8-4 and kd-18, most resistant to tebuconazole and azoxystrobin, respectively, were selected for sensitization experiments. These experiments demonstrated that combining 6-DMM with Folicur^® enhanced fungicidal effectiveness in vitro and in vivo in addition to attenuating the resistance of P. nodorum to tebuconazole in vitro. 6-DMM was also found to augment Quadris^® efficacy towards kd-18 when applied on detached wheat leaves inoculated with this strain. Experiments on P. nodorum sensitization under greenhouse conditions included preventive (applying test compounds simultaneously with inoculation) or post-inoculation spraying of wheat seedlings with 6-DMM together with Folicur^® at dose rates (DR) amounting to 10% and 20% of DR recommended for field application (RDR). Combined treatments were run in parallel with using the same DR of the fungicide and sensitizer, alone. A synergistic effect was observed in both preventive and post-inoculation treatments, when the sensitizer was co-applied with the fungicide at 10% of the RDR. In this case, disease reduction significantly exceeded the protective effect of Folicur^® at 10% or 20% of the RDR, alone, and also a calculated additive effect. Collectively, our findings suggest that 6-DMM is promising as a putative component for formulations with triazole and strobilurin fungicides. Such new formulations would improve fungicide efficacy and, potentially, lower rates of fungicides needed for plant pathogen control.

项与 YIV-906 相关的新闻（医药）

2024-08-13

·drugs

Chinese Botanical Medicine Eases a Cancer Treatment Side Effect

TUESDAY, Aug. 12, 2024 -- An experimental drug based on ancient Chinese herbal medicine can help ease the toxic side effects of chemotherapy and radiation therapy in cancer patients, the results of a small new trial results suggest. A small group of 24 patients experienced fewer GI side effects from their treatment for rectal cancer after they took YIV-906, researchers reported recently in the Journal of Gastrointestinal Oncology . YIV-906 is based on an 1,800-year-old treatment for stomach ailments that combined licorice, dates, peonies and skullcap, researchers said. “This study is the first demonstration of YIV-906’s effectiveness in reducing GI toxicity caused by chemotherapy and radiation, showing the medicine’s potential of improving the patient’s quality of life while increasing treatment effectiveness,” said co-researcher Yung-Chi Cheng , a professor of pharmacology at Yale School of Medicine who helped develop the drug. For the four-year, phase 2 study, the patients were given capsules of YIV-906 along with chemo and radiation prior to surgery. At the time of surgery, about 17% of patients had a complete or near-complete response to their cancer treatment, while the overall survival rate at five years was 82%, results show. Only two cases of severe diarrhea were reported among the patients. YIV-906 is meant to ease side effects like diarrhea, fatigue and nausea. “We didn’t have any serious toxicity associated with the drug and patients found taking the drug in pill form very easy and tolerable,” senior researcher Dr. Susan Higgins , a professor of therapeutic radiology and of obstetrics, gynecology, and reproductive sciences at Yale. The results warrant further testing of YIV-906 in more patients with other types of cancer, such as pelvic cancer, researchers said in a Yale new release. People taking YIV-906 might be able to withstand harsher doses of both chemo and radiation therapy, making their cancer treatment more effective, the researchers added. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

临床结果放射疗法临床2期

2024-02-05

·GlobeNewswire-Health Care

Yiviva Announces Memorandum of Understanding with AstraZeneca to Develop Platforms, Technologies, and Innovative Therapeutics through a Systems Biology Approach

NEW YORK and SHANGHAI, China, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Yiviva, a clinical-stage, platform biotechnology company developing systems biology medicines to treat aging-related diseases, signed a memorandum of understanding (MOU) with AstraZeneca China to establish a research and development collaboration at AstraZeneca’s Innovation Campus (iCampus) in Chengdu, China. The signing ceremony took place at the 2023 China International Import Expo (CIIE) at the National Exhibition and Convention Center in Shanghai. To address global unmet medical needs, Together Yiviva and AstraZeneca China will jointly build platforms for scientific research transformation and industrial development led by academicians and experts with the aim to modernize botanical medicines in accordance with new regulatory pathways for botanical medicines by the United States Food and Drug Administration (FDA) and China National Medical Products Administration (NMPA). “2023 marks the 30th anniversary of AstraZeneca in China. In collaboration with the Chengdu government and Chengdu High-Tech Industrial Zone (CDHT), AstraZeneca is establishing a modern healthcare development platform integrating traditional Chinese medicine and Western medicine. At CIIE, AstraZeneca announced plans to further globalize Chinese medicine. Our strategic partnership with Yiviva, will advance our blueprint for how to develop innovative medicines inspired by Chinese medicine,” remarked Lily Zhu, Vice President of AstraZeneca China and Head of DCI and CSE. “Disease knows no borders. By bringing together the knowledge and best practices of Western and Eastern Medicine, WE Medicine, we can learn from ancient wisdom to develop future medicines. Together with AstraZeneca China’s expertise, ecosystem, and resources, and Yiviva’s team, platform technologies, and pipeline, we can pioneer a new paradigm for systems biology drug development to address global unmet medical needs,” said Peikwen Cheng, Co-Founder and CEO of Yiviva. About Yiviva’s Platforms and Pipeline in Oncology Yiviva’s STAR (signal transduction, activity and response) drug discovery platform accelerates the identification of botanical therapeutics that influence immune function, inflammatory responses, cell growth, metabolic functions, and hormone activity. Through STAR, Yiviva can design sophisticated multi-target drugs that map to complicated disease biology. Yiviva has discovered six first-in-class drug candidates to treat cancer and inflammatory diseases. Yiviva applies patented, mechanism-based quality control linked to biological activity to manufacture batch-to-batch consistent drug product that satisfies established regulatory requirements for complex products. Yiviva’s lead candidate drug YIV-906 is a proprietary extract of 4 medicinal plants, inspired by an 1800-year-old traditional Chinese medicine formula. YIV-906 acts as an immunomodulator in the tumor microenvironment, turning cold tumors hot and potentiating anti-tumor activity for chemotherapies, immunotherapies, cell therapies, or radiation therapies; and acts as a cytoprotector in the gastrointestinal tract, reducing non-hematological toxicities and speeding up damaged tissue recovery. Yiviva has conducted 8 early-stage clinical trials in solid tumors (hepatocellular carcinoma, pancreatic cancer, colorectal cancer, and rectal cancers), with promising data suggesting that YIV-906 could prolong survival and improve quality of life. Yiviva recently recruited its last-patient-in in a first-line, randomized, double-blinded Phase 2b study of sorafenib plus YIV-906 in the treatment of hepatocellular carcinoma patients with hepatitis B. The CALM study is a multi-regional trial in the United States, Mainland China, Hong Kong, and Taiwan and expects a data readout in 2024. Yiviva recently published preclinical data conducted at Yale University about its novel therapeutic YIV-818-A to treat prostate cancer. YIV-818-A acts through multiple mechanisms, including androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation and could help overcome drug resistance to prostate cancer and could enhance apalutamide, darolutamide, or enzalutamide efficacy. About Yiviva Yiviva is a clinical stage, platform biotechnology company developing systems biology medicines to prevent, treat, and/or cure aging-related diseases, including cancer and inflammatory diseases. The company was launched with Yale University and Henry Bronson Professor of Pharmacology and Medicine Yung-Chi Cheng as co-founders, with teams in the United States and Greater China. Yiviva’s investors include the National Foundation for Cancer Research and the Asian Fund for Cancer Research. For further information, please visit https://yiviva.com. About AstraZeneca AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca. Contact:Email: hello@yiviva.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8d78fdf0-e819-4a98-abe1-3944978b9ad8

临床2期免疫疗法

2021-04-30

·GlobeNewswire

Advanced Liver Cancer Drug Pipeline Prospers with an Inrush

Los Angeles, USA, April 29, 2021 (GLOBE NEWSWIRE) -- Advanced Liver Cancer Drug Pipeline Prospers with an Inrush of Pharma Companies and Emerging Novel Therapies A comprehensive analysis of 50+ key companies and 50+ emerging therapies enriching the Advanced Liver Cancer Pipeline Landscape. DelveInsight’s ‘Advanced Liver Cancer Pipeline Insights’ report provides a holistic view of the pipeline therapies that are under development in pre-clinical as well as clinical stages of development and growth prospects across the Advanced Liver Cancer domain. Some of the key highlights from the Advanced Liver Cancer pipeline report are: In the News Got queries? Want to know more? Request for Sample @ Advanced Liver Cancer Clinical Trial Analysis and Pipeline Insights Advanced Liver Cancer Pipeline Activity: At a Glance Reach out @ Advanced Liver Cancer Pipeline: Novel therapies and emerging technologies Advanced Liver Cancer Pipeline Agent Assessment The Advanced Liver Cancer Pipeline report lays down holistic coverage of active pipeline assets segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Indications of various drugs. By Product Type By Stage By Molecule Type By Route of Administration By Mechanism of Action By Targets By Stage and Route of AdministrationBy Stage and Product Type For more information on emerging drugs, visit Advanced Liver Cancer Pipeline: Emerging Therapies and Trends Scope of the Report Coverage: GlobalKey Players: Siranomics, Novartis, Yiviva, Eisai, CAS Lamvac Biotech, Benhealth Biopharmaceutical, Chia Tai Tianqing Pharmaceutical, Surface Oncology, Zai Lab (Shanghai), Can-Fite Biopharma, Suzhou Zelgen Biopharmaceuticals, Innovent Biologics, SignalRX Pharmaceuticals, Carsgen Therapeutics, Shanghai Henlius Biotech, Jiangsu HengRui Medicine, Leap Therapeutics, Eureka Therapeutics, and many more.Key Advanced Liver Cancer Pipeline Therapies: STP 705, PDR001, YIV-906, H3B 6527, Plasmodium Immunotherapy, Activated CIK, AK105 Injection, SRF 388, MGD013, Namodenoson, SHR-1210, ET140203, PLM60, INC280, Donafenib, IBI308, SF1126, CAR-GPC3 T Cells, HLX10, and many more. Have a walkthrough of the report @ Advanced Liver Cancer Emerging Pipeline Key Questions Answered Need to clarify something? Get in touch @ Advanced Liver Cancer Drug Pipeline Insights Table of Contents Visit to know more of what’s covered @ Advanced Liver Cancer Emerging Therapies Other Insightful Reports Liver cancer IncidenceRead about the rising global burden of Liver Cancer. Excessive Daytime Sleepiness MarketGet a comprehensive analysis of epidemiology, pipeline therapies, and kye companies including Bioprojet Pharma/Harmony Biosciences, Axsome Therapeutics, Jazz Pharmaceuticals, BenevolentAI Bio, and many others. Bevacizumab Biosimilars InsightCoverage of about 40+ companies and 40+ marketed and pipeline drugs in Bevacizumab Biosimilars landscape. Pegfilgrastim Biosimilar InsightComprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in Pegfilgrastim Biosimilars landscape. Different Types of Alternative MedicineKnow more about the state of Alternative Medicine in Healthcare and their changing landscape. Adeno-Associated Virus (AAV) Vectors in Gene TherapyAnalysis of emerging therapies and key companies including Pfizer (previously Sangamo Biosciences), NightstaRx Ltd, a Biogen Company, MeiraGTx, Neurocrine Biosciences/ Voyager Therapeutics, Roche (previously Spark Therapeutics)/Pfizer, Sangamo Therapeutics, Freeline Therapeutics, Spark Therapeutics, Asklepios Biopharmaceutical (Actus Therapeutics), Audentes Therapeutics, Roche/Sarepta Therapeutics, Horama S.A., MeiraGTx UK II Ltd, RegenxBio, Sangamo Therapeutics, Amicus Therapeutics, Amicus Therapeutics, and several others. Angelman Syndrome MedicationsA rich analysis of emerging drug therapies and key companies such as GeneTX Biotherapeutics, LLC, Ultragenyx Pharmaceutical Inc, Hoffmann-La Roche, Ovid Therapeutics Inc., Biogen, and others involved in the Angelman Syndrome market. Get in-depth knowledge of the healthcare and pharma world through DelveInsight's Competitive Intelligence Services and Business Solutions. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. For more insights, visit Pharma, Healthcare, and Biotech News

基因疗法生物类似药免疫疗法

100 项与 YIV-906 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肿瘤	临床2期	美国	Yale University	2022-06-15
乙型肝炎	临床2期	美国	方泰达生物医药技术（北京）有限公司	2020-02-17
乙型肝炎	临床2期	美国	医起（广西）医药科技有限公司	2020-02-17
乙型肝炎	临床2期	美国	Yiviva, Inc.初创企业	2020-02-17
肝细胞癌	临床2期	美国	医起（广西）医药科技有限公司	2020-02-17
肝细胞癌	临床2期	美国	方泰达生物医药技术（北京）有限公司	2020-02-17
晚期肝细胞癌	临床2期	美国	Yiviva, Inc.初创企业	2020-01-10
晚期肝细胞癌	临床2期	中国	Yiviva, Inc.初创企业	2020-01-10
晚期肝细胞癌	临床2期	中国香港	Yiviva, Inc.初创企业	2020-01-10
晚期肝细胞癌	临床2期	中国台湾	Yiviva, Inc.初创企业	2020-01-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00730158 (CTgov)	临床2期	转移性结直肠癌	33	Irinotecan+KD018 (Arm A - Irinotecan + KD018)	鏇觸簾糧膚鬱選獵襯簾(衊窪鬱繭壓廠蓋淵鏇顧) = 遞糧廠艱鹽鏇網鹽膚鹽膚鑰衊齋膚鏇壓糧壓網 (壓築淵獵範範襯廠窪蓋, 簾積醖艱顧製餘膚顧製 ~ 淵鏇憲鏇蓋襯選醖鏇淵) 更多	-	2019-05-22
NCT00730158 (CTgov)	临床2期	转移性结直肠癌	33	Placebo+Irinotecan (Arm B - Irinotecan + Placebo)	鏇觸簾糧膚鬱選獵襯簾(衊窪鬱繭壓廠蓋淵鏇顧) = 淵構鬱築鬱襯製衊鑰壓膚鑰衊齋膚鏇壓糧壓網 (壓築淵獵範範襯廠窪蓋, 鬱網鬱壓繭範淵蓋顧餘 ~ 網積遞淵鹹網窪糧夢廠) 更多	-	2019-05-22
NCT00411762 (CTgov)	临床1/2期	胰腺癌	25	Capecitabine+PHY906	鹽鏇夢淵顧繭夢網選齋(簾糧壓鹹鹹鏇鏇鬱艱選) = 鹹鑰繭鑰鬱繭選膚簾積構憲簾齋憲鹽遞餘繭鬱 (鑰鏇窪築壓範選糧餘餘, 鹽願顧觸鑰鑰鹹餘網鑰 ~ 窪餘鏇鹹衊齋獵廠範願) 更多	-	2015-03-27
NCT04000737 (Pubmed \| Cancer Chemother Pharmacol)	临床2期	晚期胰腺腺癌二线	25	Capecitabine + PHY906	廠範遞構鹹選廠壓鬱製(選鹹願衊廠網範廠鹹網) = 淵鏇衊願顧顧醖鏇鹹齋積觸鹽鑰糧積鏇構觸網 (範築簾選膚顧鏇蓋鹽積 ) 更多	-	2014-02-01
ASCO2010	临床2期	胰腺癌	25	PHY906 plus capecitabine (CAP)	獵網艱簾願製壓憲憲築(願鑰顧製積鬱選鹽積遞) = 夢鏇願鹹獵鑰選齋膚遞夢糧繭齋鑰鬱齋衊衊醖 (淵糧鹹憲網窪築窪鏇蓋 ) 更多	-	2010-05-20
NCT04000737 (Pubmed)	临床1/2期	晚期肝细胞癌	-	PHY906	願獵獵鏇顧選窪蓋夢衊(繭簾獵製廠夢鑰襯積衊) = 糧鏇構積窪糧糧壓遞鑰積願遞廠憲廠齋襯膚膚 (願鑰鑰鹹簾觸鹹繭醖壓 ) 更多	-	2009-10-01
ASCO2009	N/A	胃肠道肿瘤	44	PHY906	鑰選鹹繭壓鏇壓願窪襯(積選鬱觸淵積獵積築遞) = 窪顧願壓鬱獵願廠憲選餘簾襯顧簾艱鹹醖醖簾 (構膚醖鏇鹽網鏇鹹鏇繭 )	-	2009-05-20
ASCO2009	N/A	胃肠道肿瘤	44	CAP alone	鑰選鹹繭壓鏇壓願窪襯(積選鬱觸淵積獵積築遞) = 衊夢積製糧網鹹製憲繭餘簾襯顧簾艱鹹醖醖簾 (構膚醖鏇鹽網鏇鹹鏇繭 )	-	2009-05-20
ASCO2007	临床1/2期	肝细胞癌	18	PHY906 + Capecitabine 1000 mg/m2 BID	網觸鏇遞襯衊鏇糧製憲(獵淵簾遞積構憲鏇鏇襯) = 範獵糧範築壓鑰遞願淵夢願鏇鹹遞衊願願願選 (壓積鏇遞襯製壓獵積範 ) 更多	-	2007-06-20
ASCO2007	临床1/2期	肝细胞癌	18	PHY906 + Capecitabine 750 mg/m2 BID	網觸鏇遞襯衊鏇糧製憲(獵淵簾遞積構憲鏇鏇襯) = 構鏇齋鹽繭鹹憲遞積鏇夢願鏇鹹遞衊願願願選 (壓積鏇遞襯製壓獵積範 ) 更多	-	2007-06-20